MA
GBT

MYDA Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

MYDA Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,000
Closed -$362K – 198
2018
Q2 		$362K Buy
+8,000
New +$364K 0.16% 107

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MYDA Advisors's GBT Position: Q3 2018 in Review

MYDA Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2018, closing a stake of 8,000 shares — an estimated $362K sold.

MYDA Advisors first reported a position in GBT in Q2 2018 and held it in 1 quarter. The position peaked at $362K in Q2 2018. 184 funds tracked by Wall St. Rank hold GBT as of Q3 2018.

  • MYDA Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • MYDA Advisors sold 8,000 Global Blood Therapeutics, Inc. shares in Q3 2018, an estimated $362K.
  • MYDA Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • MYDA Advisors's Global Blood Therapeutics, Inc. position peaked at $362K in Q2 2018.
  • 184 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2018.

Based on MYDA Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.